$21.85 0.29 (1.31%)
19:56 EST MYL Stock Quote Delayed 15 Minutes
Previous Close $21.85
Market Cap 11.70B
PE Ratio -
Volume (Avg. Vol.) 5.70M
Day's Range 21.51 - 22.35
52-Week Range 16.63 - 32.23
Dividend & Yield N/A (N/A)
MYL Stock Predictions, Articles, and Mylan News
- From InvestorPlace
- From the Web
The outgoing 2019 was truly a year to remember, with many events that will surely carry over into 2020 and beyond. Here are the stocks to buy to advantage these developments.
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
These large-cap stocks are names to avoid, particularly in a time of global recession and geopolitical tension. Bigger isn't always better.
The stock charts of NWL, HD and MYL are moving into curious positions as the trading week comes to a close.
Biotech stocks overall are holding up fairly well amid recent market volatility. Look at which four biotech stocks to buy have staying power.
News of Novo Nordisk suing Mylan is spreading as the two companies prepare for a legal battle over a generic version of Victoza.
Options trading was buzzing in Pfizer, Advanced Micro Devices and Apple on Tuesday. Here are the metrics that matter moving forward.
The stock charts of Southern Co, CF Industries Holdings and National-Oilwell Varco are at inflection points at the midpoint of the week.
The new company emerging from the Pfizer-Mylan deal gets former blockbusters like Lipitor and Celebrex, now generics, and the EpiPen business, which has been an object of scandal.
The stock charts of HBI, TRV and TPR have worked their way into pivotal position as the end of July approaches.
While it was a quiet day for the indices, there were a lot of moves under the surfaces to take note of in the stock market today.
A new Mylan-Pfizer deal that will have the companies taking part in a merger agreement has MYL stock heading higher on Monday.
It looks like there is no end is sight to the EpiPen shortage and Mylan (MYL) stock is taking a beating Wednesday on the news.
Biotech rallied on a $63 billion deal between AbbVie and Allergan. But other than that, it was a tough day for the Nasdaq today.
The stock charts of DISH, FFIV and CRM stock are headed into hump-day on the verge of major moves. Here's what you can expect.
Realty Income, Allergan, Boeing, Mylan and the S&P 500 were big movers on Tuesday. You have to see these must-see stock charts.
The stock charts of CELG, AAL and MYL stock are going to start the new trading week out in a clear technical condition.
Generic drug companies are on discount for investors who want to buy life sciences stocks. Why, and when will this sector recover?
Mylan stock is getting smashed after its fourth-quarter earnings results and full-year outlook. MYL stock could still go lower, though.
From The Motley Fool
From Market News Video
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader